Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acucela
Acucela Highlights Data to Be Presented at ARVO
May 15th, 2009
Acucela announced it will present new data on ACU-4429, an investigational therapy for dry age-related macular degeneration (AMD), at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in Fort Lauderdale, Florida from May 3 to May 7, 2009. Data will be presented on the safety, tolerability and effectiveness of ACU-4429, a single-dose daily oral treatment for dry AMD, the most common form of the disease. All forms (wet and dry) of age-related macular degeneration affect more than 1.75 million people in the United States and are expected to increase to almost 3 million by 20201. Currently, there is no approved medicinal therapeutic...
Source: Health Business Week (2009-05-15)
|
